BR112019012084A2 - uso médico de interferon-lambda para o tratamento de fibrose - Google Patents

uso médico de interferon-lambda para o tratamento de fibrose

Info

Publication number
BR112019012084A2
BR112019012084A2 BR112019012084-0A BR112019012084A BR112019012084A2 BR 112019012084 A2 BR112019012084 A2 BR 112019012084A2 BR 112019012084 A BR112019012084 A BR 112019012084A BR 112019012084 A2 BR112019012084 A2 BR 112019012084A2
Authority
BR
Brazil
Prior art keywords
fibrosis
interferon
lambda
treatment
medical use
Prior art date
Application number
BR112019012084-0A
Other languages
English (en)
Inventor
Twomey Breda
Powers Janine
Scott Johnson Timothy
Original Assignee
Five Prime Therapeutics Inc
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc, Ucb Biopharma Sprl filed Critical Five Prime Therapeutics Inc
Publication of BR112019012084A2 publication Critical patent/BR112019012084A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a presente invenção refere-se a métodos para o tratamento de fibrose. a invenção divulga nova pesquisa que demonstra que o interferon-lambda tem efeitos antifibróticos de ação direta tanto in vitro quanto in vivo e pode ser usado para prover novas terapias eficazes para o tratamento de tipos múltiplos de fibrose.
BR112019012084-0A 2016-12-20 2017-12-20 uso médico de interferon-lambda para o tratamento de fibrose BR112019012084A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1621728.3A GB201621728D0 (en) 2016-12-20 2016-12-20 Methods
PCT/EP2017/083949 WO2018115199A1 (en) 2016-12-20 2017-12-20 Medical use of interferon-lambda for the treatment of fibrosis

Publications (1)

Publication Number Publication Date
BR112019012084A2 true BR112019012084A2 (pt) 2019-11-12

Family

ID=58284677

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019012084-0A BR112019012084A2 (pt) 2016-12-20 2017-12-20 uso médico de interferon-lambda para o tratamento de fibrose

Country Status (12)

Country Link
US (2) US20190374610A1 (pt)
EP (1) EP3558342A1 (pt)
JP (2) JP2020511415A (pt)
CN (1) CN110381985A (pt)
AR (1) AR110404A1 (pt)
BR (1) BR112019012084A2 (pt)
CA (1) CA3044949A1 (pt)
EA (1) EA201991175A1 (pt)
GB (1) GB201621728D0 (pt)
TW (1) TW201828973A (pt)
UY (1) UY37534A (pt)
WO (1) WO2018115199A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3849592A4 (en) * 2018-08-23 2022-08-24 Exalt Therapeutics, LLC MODIFIED IFNL3 POLYPEPTIDES WITH A PHARMACOKINETIC ENHANCEMENT PART AND THEIR USES
EP3999101A1 (en) 2019-07-18 2022-05-25 ENYO Pharma Method for decreasing adverse-effects of interferon
CN110882381B (zh) * 2019-12-18 2020-11-17 中国人民解放军陆军军医大学第一附属医院 重组IFN-λ1蛋白在制备防治炎症性骨丢失药物中的应用
US20220378878A1 (en) * 2019-12-20 2022-12-01 The Council Of The Queensland Institute Of Medical Research Treatment of gastrointestinal disease
CN114736878B (zh) * 2021-01-07 2024-04-19 秦皇岛摩登狗生物科技有限公司 共表达猪干扰素l3和猪白介素22重组杆状病毒及应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
HUP0303645A3 (en) 2001-04-06 2005-12-28 Maxygen Holdings Ltd Georgetow Interferon gamma polypeptide variants
US20060110358A1 (en) 2002-08-28 2006-05-25 Hsu Henry H Combination therapy for treatment of fibrotic disorders
AU2003299962A1 (en) 2003-02-28 2004-09-28 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
AU2003225670A1 (en) 2003-02-28 2004-09-28 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
WO2004105684A2 (en) 2003-05-16 2004-12-09 Intermune, Inc. Combination therapy for proliferative disorders
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CA2527020A1 (en) 2003-07-01 2005-01-13 Celltech R & D Limited Modified antibody fab fragments
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US20070258946A1 (en) * 2003-12-23 2007-11-08 Blatt Lawrence M Combination Therapy for Treating Hepatitis C Virus Infection
WO2005110478A2 (en) 2004-04-13 2005-11-24 Intermune, Inc. Combination therapy for treating fibrotic disorders
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
CA2644127A1 (fr) 2006-03-08 2007-09-13 Biomethodes Variants ameliores de l'interferon-gamma humain (ifny)
CN104004088B (zh) 2007-09-26 2017-11-07 Ucb医药有限公司 双特异性抗体融合物
WO2009149377A1 (en) * 2008-06-05 2009-12-10 Zymogenetics, Llc Use of pegylated type iii interferons for the treatment of hepatitis c
US20110263484A1 (en) 2008-10-13 2011-10-27 Zymogenetics, Inc. Single chain fc type iii interferons and methods of using same
WO2010048468A1 (en) 2008-10-23 2010-04-29 Concert Pharmaceuticals, Inc. Deuterated macrocyclic inhibitors of viral ns3 protease
WO2010059984A1 (en) * 2008-11-20 2010-05-27 Zymogenetics, Llc Il-29 mutants and uses thereof
WO2011075605A2 (en) * 2009-12-18 2011-06-23 Alios Biopharma, Inc. Hyperglycosylated interferon variants and methods of use
IT1400236B1 (it) 2010-05-10 2013-05-24 Univ Bari Impiego di composti noti per il trattamento dell'insufficienza renale cronica(irc)
CN102584979B (zh) * 2011-01-18 2015-10-14 北京凯因科技股份有限公司 PEG化干扰素λ
EP2831106B1 (en) 2012-03-28 2020-07-15 The United States of America, as represented by The Secretary, Department of Health and Human Services A novel interferon-lambda 4 (ifnl4) protein, related nucleic acid molecules, and uses thereof
PT3416675T (pt) * 2016-02-19 2021-06-14 Eiger Biopharmaceuticals Inc Tratamento de infeção pelo vírus da hepatite delta com interferão lambda

Also Published As

Publication number Publication date
AR110404A1 (es) 2019-03-27
WO2018115199A1 (en) 2018-06-28
CA3044949A1 (en) 2018-06-28
EA201991175A1 (ru) 2019-11-29
TW201828973A (zh) 2018-08-16
US20240000893A1 (en) 2024-01-04
US20190374610A1 (en) 2019-12-12
CN110381985A (zh) 2019-10-25
GB201621728D0 (en) 2017-02-01
US11975046B2 (en) 2024-05-07
JP2020511415A (ja) 2020-04-16
UY37534A (es) 2018-09-28
EP3558342A1 (en) 2019-10-30
JP2022081677A (ja) 2022-05-31

Similar Documents

Publication Publication Date Title
BR112019012084A2 (pt) uso médico de interferon-lambda para o tratamento de fibrose
BR112017011536A2 (pt) terapias de combinação
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
CL2015002807A1 (es) Terapia de combinación
BR112016006978A2 (pt) inibidores de tirosina quinase de bruton
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
BR112016017700A2 (pt) método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit
BR112015011830A2 (pt) compostos e seus métodos de utilização
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
PH12019501010A1 (en) Arginase inhibitor combination therapies
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
MX2018005544A (es) Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar cancer.
MX2017002364A (es) Terapia de combinacion para tratamiento de cancer.
BR112018007671A2 (pt) terapia de combinação para tratamento de malignidades
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112016006851A2 (pt) método de seleção de um agente para prevenção ou tratamento da esclerose lateral amiotrófica (ela), método de tratamento ou prevenção da progressão da ela em um indivíduo em mecessidade deste e uso de uma população celular de astrócitos progenitores humanos ou astrócitos
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
MX2019004402A (es) Metodos para el tratamiento de las condiciones relacionadas con la inflamacion utilizando moduladores antiinflamatorios y metabolicos pluripotentes.
MX2018005628A (es) Tratamientos de grasa acumulada con acido desoxicolico y sales del mismo.
BR112017013674A2 (pt) métodos e composições para tratamento de doenças cerebrais.
BR112016026510A2 (pt) Dispositivo e formulação para tratamento tópico da dor que afeta a área vulvar do órgão genital feminino
EA201390287A1 (ru) Теобромин в комбинации с отхаркивающим или муколитическим средствами для применения в терапии
BR112018010066A8 (pt) Agente estimulante do receptor 5-hidroxitriptamina 1b para intensificar potencial de enxerto in vivo
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: FIVE PRIME THERAPEUTICS, INC. (US) ; UCB BIOPHARMA SRL (BE)

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2703 DE 25-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.